Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6417945 | 0.90 | NPC1 (0.35) | NPC1RAB9ACHRNA7KDM4ESMN1; SMN2 | |
| SCHEMBL6413615 | 0.86 | HPGDS (0.38) | NPC1RAB9ACHRNA7KDM4ESMN1; SMN2 | |
| SCHEMBL6415275 | 0.85 | NPC1 (0.40) | NPC1RAB9ACHRNA7KDM4ESMN1; SMN2 | |
| SCHEMBL6415941 | 0.85 | NPC1 (0.36) | NPC1RAB9ACHRNA7KDM4ESMN1; SMN2 | |
| SCHEMBL6417451 | 0.85 | NPC1 (0.38) | NPC1RAB9ACHRNA7KDM4ESMN1; SMN2 | |
| SCHEMBL6417962 | 0.82 | SLC6A2 (0.35) | NPC1RAB9ACHRNA7CHRM4 | |
| SCHEMBL6415405 | 0.82 | NPC1 (0.33) | NPC1RAB9A | |
| SCHEMBL6415961 | 0.80 | NAMPT (0.45) | CHRNA7HTR3A | |
| SCHEMBL6418629 | 0.80 | CHRNA7 (0.39) | CHRNA7HTR3A | |
| SCHEMBL6414994 | 0.80 | CHRNA7 (0.33) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC | 2005-09-29 | — | — | US | disclosed |
| US-6858613-B2 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | NAT1, CYP11B1, COASY | NPC1 142/4885RAB9A 2031/4885CHRNA7 1475/4885 |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | CHRNA7, UGT2B7, CHRNA5 | NPC1 221/4885RAB9A 871/4885CHRNA7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.